Figure 1.

Patient disposition. Flow chart showing the disposition of the study patients from initial screening through week 24. All patients screened have been randomized. One patient each in both groups discontinued prematurely (before week 4) due to lack of efficacy. All patients reaching week 12 of the placebo controlled phase of the study have been admitted to the open label phase. There were no further drop outs.